Longevity InTime: Autonomous AI Institute. Anti-Aging Digital Health Immortality Transhumanist AI Channel

Pixelgen Funding Pixelgen has raised $15.5 million to commercialize the measurement of protein neighborhood on the surface of individual cells. On August 20, Pixelgen announced a Series B round of $15.5 million, led by Flat Capital, with existing investors Industrifonden and Navigare Ventures participating. The company will use the funds for global commercialization of the Proxiome Kit, team expansion, and product portfolio growth. The surface of a cell contains proteins that receive external signals and respond to them. Traditional single-cell analysis counts which proteins are present in a cell and how many there are. The Proxiome Kit adds arrangement information: which proteins cluster together and which are nearby on the cell membrane. The kit is based on the Proximity Network Assay. Cells are fixed, then antibodies with DNA barcodes bind to selected surface proteins. The barcodes are copied multiple times near the binding site, and neighboring copies are connected and read by sequencing - a method of reading DNA sequences. In a preprint, the authors described a panel of 155 plasma membrane proteins and applied the method to blood cells, blood cancer cell lines, CAR-T models, and autoimmune disease samples. In one cell, they obtained tens of thousands of spatial nodes and around 12 thousand pairwise relationships between proteins. A single sample provides both a traditional list of protein markers and a scheme of their neighborhood on the cell surface. Pixelgen is bringing this measurement method to a commercial kit, as described in preprint, August 2026. Laboratories will be able to compare cells not only by their protein set but also by how these proteins are arranged next to each other. 🔗 Read original →